133 related articles for article (PubMed ID: 31144267)
1. Establishment and characterization of a novel cell line of medullary thyroid carcinoma from a dog.
Okano K; Uematsu Y; Nibe K; Yamashita M; Suzuki S; Uchida K; Ono K; Hirao H
In Vitro Cell Dev Biol Anim; 2019 Aug; 55(7):559-566. PubMed ID: 31144267
[TBL] [Abstract][Full Text] [Related]
2. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
[TBL] [Abstract][Full Text] [Related]
4. RET Gene Analysis in Patients with Medullary Thyroid Carcinoma.
Kheiroddin P; Rasihashemi SZ; Estiar MA; Mahmudian B; Halimi M; Mousavi F; Nemati M; Sakhinia E
Clin Lab; 2016; 62(5):871-6. PubMed ID: 27349013
[TBL] [Abstract][Full Text] [Related]
5. [
Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
[TBL] [Abstract][Full Text] [Related]
6. High-resolution analysis of alterations in medullary thyroid carcinoma genomes.
Flicker K; Ulz P; Höger H; Zeitlhofer P; Haas OA; Behmel A; Buchinger W; Scheuba C; Niederle B; Pfragner R; Speicher MR
Int J Cancer; 2012 Jul; 131(2):E66-73. PubMed ID: 22038905
[TBL] [Abstract][Full Text] [Related]
7. Medullary and papillary thyroid carcinomas in a patient with a C634Y mutation in the RET proto-oncogene: A case report.
Ding Y; Feng J; Xu XH; Yao J; Ying RB
Indian J Cancer; 2019; 56(2):173-175. PubMed ID: 31062739
[TBL] [Abstract][Full Text] [Related]
8. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
Giardino E; Catalano R; Mangili F; Barbieri AM; Treppiedi D; Elli FM; Dolci A; Contarino A; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2021 Jan; 520():111092. PubMed ID: 33248230
[TBL] [Abstract][Full Text] [Related]
9. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
11. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
[TBL] [Abstract][Full Text] [Related]
12. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M
Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133
[TBL] [Abstract][Full Text] [Related]
13. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
14. Expression of Prox1 in Medullary Thyroid Carcinoma Is Associated with Chromogranin A and Calcitonin Expression and with Ki67 Proliferative Index, but Not with Prognosis.
Saglietti C; La Rosa S; Sykiotis GP; Letovanec I; Bulliard JL; Piana S; Mermod M; Petrova T; Uccella S; Sessa F; Bongiovanni M
Endocr Pathol; 2019 Jun; 30(2):138-145. PubMed ID: 31001799
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
Kumarasamy VM; Sun D
Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of RET receptor tyrosine kinase and non-coding RNAs in MTC.
Joo LJS; Zhao JT; Gild ML; Glover AR; Sidhu SB
Mol Cell Endocrinol; 2018 Jul; 469():48-53. PubMed ID: 28315378
[TBL] [Abstract][Full Text] [Related]
17. Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.
Gursoy A; Erdogan MF; Erdogan G
J Endocrinol Invest; 2006 Nov; 29(10):858-62. PubMed ID: 17185892
[TBL] [Abstract][Full Text] [Related]
18. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
[TBL] [Abstract][Full Text] [Related]
19. MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET.
Duan L; Hao X; Liu Z; Zhang Y; Zhang G
FEBS Lett; 2014 May; 588(9):1644-51. PubMed ID: 24631532
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
